The merger between Serum Institute of India subsidiary Covidshield Technologies and Biocon Biologics has finally completed, subject to requisite approvals, after a Biocon board meeting.
Biocon has announced the merger of its subsidiary Biocon Biologics Ltd with the Serum Institute of India’s subsidiary Covidshield Technologies, subject to requisite statutory approvals. The merger was confirmed in early January at a Biocon board meeting, after the deal was first announced in September.
[Sidebar#SC145086]
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
